PubMed=3434911; DOI=10.2460/ajvr.1987.48.11.1642
Wolfe L.G., Oliver J.L. 3rd, Smith B.B., Toivio-Kinnucan M.A., Powers R.D., Brawner W.R., Henderson R.A., Hankes G.H.
Biologic characterization of canine melanoma cell lines.
Am. J. Vet. Res. 48:1642-1648(1987)

PubMed=15965647; DOI=10.1007/s00262-005-0025-6; PMCID=PMC11031070
Alexander A.N., Huelsmeyer M.K., Mitzey A., Dubielzig R.R., Kurzman I.D., MacEwen E.G., Vail D.M.
Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma.
Cancer Immunol. Immunother. 55:433-442(2006)

PubMed=22901430; DOI=10.1016/j.jcpa.2012.07.001; PMCID=PMC3535688
Chon E., Thompson V., Schmid S., Stein T.J.
Activation of the canonical Wnt/beta-catenin signalling pathway is rare in canine malignant melanoma tissue and cell lines.
J. Comp. Pathol. 148:178-187(2013)

PubMed=23410087; DOI=10.1111/vco.12019
Wilson-Robles H.M., Daly M., Pfent C., Sheppard-Olivares S.
Identification and evaluation of putative tumour-initiating cells in canine malignant melanoma cell lines.
Vet. Comp. Oncol. 13:60-69(2015)